-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Hold on Quest Diagnostics, Raises Price Target to $260

Benzinga·09/21/2026 13:07:51
语音播报
Truist Securities analyst David Macdonald maintains Quest Diagnostics (NYSE:DGX) with a Hold and raises the price target from $250 to $260.